The REVEAL-SCAN Project

Alzheimer’s disease (AD) clinical trials have traditionally tested individuals with symptoms of dementia, but the discovery of AD biomarkers has dramatically altered this approach. New studies are enrolling participants who are cognitively normal but have biomarkers suggestive of “preclinical AD” with the hopes of delaying the onset of cognitive impairment. Of critical importance is whether … Continued

Publications

2021

How will Aducanumab approval impact Alzheimer’s disease research?

Weiner MW, Aisen PS, Beckett LA, Green RC, Jagust William, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Mindt MR, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ and the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Journal of Prevention of Alzheimer's Disease Jul 2021